Acquisition by Integra LifeSciences of regenerative medicine company ACell – Global Legal Chronicle

Sullivan & Cromwell LLP advised Integra LifeSciences Holdings Corporation on the transaction.

Integra LifeSciences Holdings Corporation completed the acquisition of ACell Inc. on January 20 for an upfront cash payment of $ 300 million and additional cash payments of up to $ 100 million upon achieving certain growth milestones in income.

Integra LifeSciences is a global leader in medical technology, providing innovative solutions, including advanced regenerative technologies, in specialized surgical solutions, orthopedics and tissue technologies.

ACell is an innovative regenerative medicine company with a product portfolio based on a proprietary porcine urinary bladder matrix platform technology, MatriStem UBMTM. The acquisition of ACell is the next step in the expansion of Integra’s orthopedic and tissue technologies segment.

The S&C team advising on M&A matters was led by Melissa Sawyer (Photo) and included partners Benjamin Goodchild and Beini Chen. Davis Wang has advised on tax matters; Heather Coleman provided advice on executive compensation; Mehdi Ansari has advised on intellectual property issues; Renata Hesse advised on antitrust matters; special advocate Eric Queen advised on RSS issues; and Special Counsel Matt Brennan advised on warranty representation and insurance matters.

Remunerator of the costs involved: Mehdi Ansari – Sullivan & Cromwell; Matthew Brennan – Sullivan & Cromwell; Heather Coleman – Sullivan & Cromwell; Benjamin Goodchild – Sullivan & Cromwell; Renata Hesse – Sullivan & Cromwell; Eric Reine – Sullivan & Cromwell; Melissa Sawyer – Sullivan & Cromwell; Davis Wang – Sullivan & Cromwell;

Law firms: Sullivan & Cromwell;

Customer base : Holding company Integra LifeSciences;